Untreated Chronic Lymphocytic Leukemia
Oncology·MeSH: Leukemia, Lymphocytic, Chronic, B-Cell
Prevalence
20.0 / 100K
Incidence
4.7 / 100K/yr
3 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Phase 3(2)
Phase 4(1)
| Drug | Company |
|---|---|
| Acalabrutinib | ASTRAZENECA PLC (AZN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Untreated Chronic Lymphocytic Leukemia?
BioSniper tracks 3 drugs in development for Untreated Chronic Lymphocytic Leukemia across 2 companies.
How many clinical trials target Untreated Chronic Lymphocytic Leukemia?
There are 1 clinical trial targeting Untreated Chronic Lymphocytic Leukemia tracked by BioSniper.
What is the prevalence of Untreated Chronic Lymphocytic Leukemia?
The estimated prevalence of Untreated Chronic Lymphocytic Leukemia is approximately 20.0 per 100,000 population.
Deep-dive into Untreated Chronic Lymphocytic Leukemia
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis